BioTime, Inc: Lead (Ph 2) cell replacement candidate: OpRegen®, retinal pigment epithelium transplant therapy: Dry AMD. Lead cell delivery clinical program: Renevia®: med device developed as alternative to adipose tissue transfer procedures. Equity in Asterias Biotherapeutics (NYSE: AST), OncoCyte Corporation (NYSE: OCX), and AgeX Therapeutics (private)
Website:
Address:
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.